AP-202
Advanced Solid Tumors
Phase 1/2Active, dose expansion
Key Facts
Indication
Advanced Solid Tumors
Phase
Phase 1/2
Status
Active, dose expansion
Company
About Advance Pharmaceutical
Advance Pharmaceutical is dedicated to translating scientific discoveries into transformative medicines for patients with high unmet medical needs. The company's core technology enables the precise targeting of disease pathways, particularly in oncology and genetic disorders. With a robust pipeline of candidates in various stages of development and a strong leadership team, the company is strategically positioned for growth. Its focus on both internal development and strategic partnerships aims to accelerate the delivery of new therapies to market.
View full company profileTherapeutic Areas
Other Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| NST-101 (estimated) | Novastage Pharmaceuticals | Phase 1/2 |
| Meta10-TILs | Leman Biotech | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| Ecubectedin (PM54) | PharmaMar | Phase 1 |
| M8891 | Merck KGaA | Phase 1/2 |
| P-002 | Panacea Biotec | Phase 1/2 |
| Undisclosed kinase inhibitor | Tyligand Bioscience | Phase 1 |
| TYK-001 | TYK Medicines | Phase 1/2 |
| PT-112 | SciClone Pharmaceuticals | Phase 1 |
| BP1001-A | Bio-Path Holdings | Phase 1 |